Milestone

We continuously accelerate our R&D efforts by leveraging top talent and cutting-edge resources to realize our vision in personalised cancer treatment. 

As of June 2024, we have secured US$1.5 million funding for product development and retrospective clinical studies as our primary mission. Find out more at www.provectustherapeutics.com.